There is much post-Brexit talk of using our new-found political independence to liberalise clinical trials in the U.K. We can cut ourselves free of all that terrible EU red-tape that has weighed us down. Or so the argument goes. We can be quicker and more efficient than other countries. We will be more attractive to … Continue reading The post-Brexit liberalisation of #clinicaltrials could be the way to a bolder ambition for the UK
Brexit
Patients and the public are vital to science’s role in a post #Brexit Britain. A response to Pfizer’s MD, Erik Nordkamp
I do try to live up to my Tunbridge Wells postcode by firing off regular 'disgusted' letters to the press and, in particular, The Daily Telegraph (DT). On Monday Erik Nordkamp, Pfizer's Managing Director, wrote this article about the importance of the life sciences industry to a post-Brexit economic strategy. So I sent this to … Continue reading Patients and the public are vital to science’s role in a post #Brexit Britain. A response to Pfizer’s MD, Erik Nordkamp
Brexit and UK science: a cartoon
I wouldn't pretend to be a cartoonist (as if I need to say that!). But in a week when there has been much talk about the impact of Brexit on UK science, this cartoon sprung to mind. Composed on my early morning walk with the dog. Keep the faith.
